Major advancements in hemophilia treatments include longer-lasting recombinant coagulation factors and effective monoclonal antibodies that reduce bleeding episodes. While gene therapy shows promise as a potential cure by replacing defective genes, challenges such as cost and global availability remain significant hurdles. Current trials for both hemophilia A and B are encouraging, paving the way for a brighter future for those affected by the disease.
